Last reviewed · How we verify
NCT06807151
Leveraging Plasma Concentration Levels to Optimize Extracorporeal Treatment in Acute Diquat Poisoning
trial testing Extracorporeal Treatment in Diquat Poisoning in 163 participants. Completed in 12 April 2025.
31 July 2023
Quick facts
| Lead sponsor | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 163 |
| Start date | 1 February 2022 |
| Primary completion | 31 July 2023 |
| Estimated completion | 12 April 2025 |
| Sites | 1 location across China |
Drugs / interventions tested
- Extracorporeal Treatment
Conditions studied
- Diquat Poisoning — all drugs for Diquat Poisoning →
- Blood Purification — all drugs for Blood Purification →
Sponsor
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Who can join
Eligibility, any sex, with Diquat Poisoning or Blood Purification. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This study aimed to evaluate the clinical value of plasma diquat concentration in guiding personalized extracorporeal treatment regimens for patients with acute diquat poisoning.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06807151
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Extracorporeal Treatment
Trials testing the same drug.
- NCT06798129 — Effects of Extracorporeal Treatment in Patients With Acute Poisoning · active not recruiting
Other recruiting trials for Diquat Poisoning
Currently open trials in the same condition.
- NCT06798142 — Risk Stratification and Heterogeneity for Organ Damage in Acute Diquat Poisoning · active not recruiting
Other The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School trials
Trials by the same sponsor.
- NCT06966765 — Accelerated vs Standard Approach to Continuous Veno-venous Hemodiafiltration Post-hemoperfusion (ASAP) in Severe Acute D · Phase 3 · not yet recruiting
- NCT07403071 — Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Expe · not yet recruiting
- NCT07532538 — A Machine Learning-Based Risk Prediction Model for Head and Neck Cancerous Lesions · not yet recruiting
- NCT07353645 — KRAS Neoantigen Nanovaccine as Adjuvant Therapy for Colorectal Cancer/Pancreatic Cancer · Phase 1, PHASE2 · recruiting
- NCT07399574 — Diagnostic Accuracy of A Diquat Quantitative Detection Kit and A Portable Mass Spectrometry System for Quantifying Diqua · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06807151 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- Last refreshed: 22 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06807151.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing